## Biocatalysis

## **25-Hydroxyvitamin D<sub>3</sub> Synthesis by Enzymatic Steroid Side-Chain Hydroxylation with Water**

Markus Warnke, Tobias Jung, Juri Dermer, Karin Hipp, Nico Jehmlich, Martin von Bergen, Sascha Ferlaino, Alexander Fries, Michael Müller, and Matthias Boll\*

Dedicated to Georg Fuchs on the occasion of his 70th birthday

Abstract: The hydroxylation of vitamin  $D_3$  (VD<sub>3</sub>, cholecalciferol) side chains to give 25-hydroxyvitamin  $D_3$  (250HVD<sub>3</sub>) is a crucial reaction in the formation of the circulating and biologically active forms of VD<sub>3</sub>. It is usually catalyzed by cytochrome P450 monooxygenases that depend on complex electron donor systems. Cell-free extracts and a purified Mo enzyme from a bacterium anaerobically grown with cholesterol were employed for the regioselective, ferricyanide-dependent hydroxylation of  $VD_3$  and pro $VD_3$  (7-dehydrocholesterol) into the corresponding tertiary alcohols with greater than 99 % yield. Hydroxylation of VD<sub>3</sub> strictly depends on a cyclodextrinassisted isomerization of  $VD_3$  into pre $VD_3$ , the actual enzymatic substrate. This facile and robust method developed for 250HVD<sub>3</sub> synthesis is a novel example for the concept of substrate-engineered catalysis and offers an attractive alternative to chemical or  $O_2$ /electron-donor-dependent enzymatic procedures.

Vitamin D<sub>3</sub> (VD<sub>3</sub>, cholecalciferol, 1) is generally known for its regulatory function in calcium and phosphorous homeostasis, but it is also recognized as an antiproliferative factor in dividing cells and tissues.<sup>[1]</sup> VD<sub>3</sub> is formed from proVD<sub>3</sub> (7dehydrocholesterol, 3) by UV-B irradiation to give the *seco* form, followed by a thermal [1,7] signatropic hydrogen shift. It is converted into its biologically active form by consecutively acting cytochrome P450 monooxygenases (CYPs): hydroxylation in the liver yields 25-hydroxy-VD<sub>3</sub> (250HVD<sub>3</sub>, calcidiol, 2), which is converted into calcitriol  $(1\alpha,25(OH)_2VD_3)$  in the kidney. Insufficient levels of biologically active VD<sub>3</sub> are linked to numerous forms of cancer but

[\*] M. Sc. M. Warnke, T. Jung, Dr. J. Dermer, K. Hipp, Prof. Dr. M. Boll Faculty of Biology - Microbiology Albert-Ludwigs-Universität Freiburg Schänzlestrasse 1, 79104 Freiburg (Germany) E-mail: matthias.boll@biologie.uni-freiburg.de
S. Ferlaino, Dr. A. Fries, Prof. Dr. M. Müller Institute of Pharmaceutical Sciences Albert-Ludwigs-Universität Freiburg Albertstrasse 25, 79104 Freiburg (Germany)
Dr. N. Jehmlich, Prof. Dr. M. von Bergen Department of Proteomics Helmholtz Centre of Environmental Sciences Permoserstr. 15, 04318 Leipzig (Germany)
Image: Supporting information for this article (including experimental

Supporting information for this article (including experimental details) is available on the WWW under http://dx.doi.org/10.1002/ anie.201510331.

also to cardiovascular diseases, immunodeficiency, and diabetes.<sup>[2]</sup> 25OHVD<sub>3</sub> (**2**) represents the circulating form of VD<sub>3</sub>, and its plasma concentration has been associated with VD<sub>3</sub>-linked disorders.<sup>[3]</sup>

Classical chemical 25OHVD<sub>3</sub> (**2**) synthesis procedures involve multiple steps with low yields and specificities,<sup>[4]</sup> although recently more convenient procedures, for example, methods involving anchoring on a solid phase, have been developed.<sup>[5]</sup> For enzymatic synthesis, CYPs either from liver, fungi, or actinomycetes have been employed.<sup>[6]</sup> However, the dependence on complex electron-donor systems consisting of NAD(P)H, ferredoxin (Fd), and ferredoxin reductase (FdR) has limited biotechnological applications; promising approaches employ whole cells expressing the genes encoding CYP, Fd, and FdR (Scheme 1 A). As an alternative, an H<sub>2</sub>O<sub>2</sub>dependent peroxygenase has been used for hydroxylation of low concentrations of VD<sub>3</sub> and ergocalciferol (VD<sub>2</sub>; Scheme 1 B).<sup>[7]</sup>



**Scheme 1.** Enzymatic conversions of VD<sub>3</sub> (1) and proVD<sub>3</sub> (3) into 25OHVD<sub>3</sub> (2) and 25OHproVD<sub>3</sub> (4), respectively. A) Hydroxylation of 1 by O<sub>2</sub>-dependent CYPs in the presence of an electron-donor system including NAD(P)H, Fd, and FdR. B) Hydroxylation of 1 by H<sub>2</sub>O<sub>2</sub>-dependent peroxygenase. C, D) Water- and K<sub>3</sub>[Fe(CN)<sub>6</sub>]-dependent hydroxylation of 1 and 3 by C25DH. (A) and (B) were previously established,<sup>[6,7]</sup> (C) and (D) were studied in this work.

A fundamentally different mode of enzymatic steroid side-chain hydroxylation was identified during the anaerobic degradation of cholesterol to  $CO_2$  in the denitrifying bacterium *Sterolibacterium denitrificans*: the regioselective hydroxylation of cholesterol into 25-hydroxycholesterol with

Angew. Chem. Int. Ed. 2016, 55, 1881-1884

© 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

water catalyzed by steroid C25 dehydrogenase (C25DH).<sup>[8]</sup> This enzyme belongs to the DMSO reductase (DMSOR) family of Mo enzymes that catalyze O2-independent hydroxyand oxo-transfer reactions.<sup>[9]</sup> A C-H bond functionalization with water to a tertiary alcohol via a carbocation transition state has been proposed.<sup>[8]</sup> C25DH transfers electrons to electrochemically regenerative electron acceptors such as  $K_3[Fe(CN)_6]$  (Scheme 1 C). The genome of S. denitrificans contains at least eight homologous genes encoding putative Mo-dependent steroid hydroxylases,<sup>[8]</sup> thus making this organism a promising biological platform for water-dependent hydroxylations of various steroids. In this work, we explored the use of S. denitrificans enzyme(s) for regioselective synthesis of the biologically relevant hydroxylated forms of  $VD_3$  (1) and proVD<sub>3</sub> (3). The hydroxylated 25OHproVD<sub>3</sub> (4, Scheme 1 D) can easily be converted into  $250HVD_3$  (2) by established UV irradiation methods.[10]

In the presence of 2-hydroxypropyl- $\beta$ -cyclodextrin (HPCD), crude extracts from *S. denitrificans* anaerobically grown with cholesterol catalyzed the K<sub>3</sub>[Fe(CN)<sub>6</sub>]-dependent conversion of VD<sub>3</sub> (1) and proVD<sub>3</sub> (3) into the single products 2 and 4 (Figure 2 A, B), respectively, with substrate conversions of >99% (2) and 97% (4; Figure 1 A, B). After the



*Figure 1.* Enzyme assays for the hydroxylation of 1 and 3. A, B) Ultraperformance liquid chromatography (UPLC) analysis of the enzymatic conversion of 1 and 3 into their hydroxylated products 2 and 4, respectively. C, D) UV spectra of 1–4.

conversion of VD<sub>3</sub> (1) reached 92% (16 h), the product **2** was slowly degraded by unspecific enzymatic reactions, which could be fully prevented by the addition of 0.5 mM AgNO<sub>3</sub>, a known inhibitor of the downstream reactions of steroid catabolism.<sup>[8]</sup> The UV/Vis spectra of the products were identical to those of the substrates, which is in agreement with side-chain hydroxylations distant from the conjugated triene (**1**) and diene (**3**) chromophors (Figure 1 C, D).

Conversion of **1** and **3** was HPCD dependent, with an optimum at 15% (*w*/*v*; Figure 2C). The initial rate of the reaction followed Michaelis–Menten kinetics, with  $v_{max} = 1.48 \pm 0.05$  nmolmin<sup>-1</sup> per mg crude extract protein for VD<sub>3</sub> (**1**), which is threefold higher than the rate of proVD<sub>3</sub> (**3**) conversion ( $0.47 \pm 0.02$  nmolmin<sup>-1</sup> per mg crude extract protein; Figure 2D). The conversions of **1** and **3** were strictly



**Figure 2.** Properties of the enzymatic hydroxylation of 1 and 3. A) Time-dependent conversion of 1 into 2 in the presence of 0.5 mm AgNO<sub>3</sub>. B) Time-dependent conversion of 3 into 4. Both reactions contained 15% HPCD C) HPCD dependence of the conversion of 1 and 3. D) Substrate concentration dependence of the conversion of 1 and 3.

dependent on electron acceptors with standard redox potentials higher than 200 mV, such as  $[Fe(CN)_6]^{3-}$  (ferricyanide), with the highest initial rates between 5–10 mM K<sub>3</sub>[Fe(CN)<sub>6</sub>]. This rather high value can be explained by competing unspecific K<sub>3</sub>[Fe(CN)<sub>6</sub>] oxidizing reactions in cell extracts.

The products formed from **1** and **3** were analyzed by chemical ionization mass spectrometry. For the product of **1** ( $M_r$ =384.65), compound **2**, an ion with m/z [M+H]<sup>+</sup> of 401.3, was determined, thus indicating the addition of a hydroxy group (Figure S1 in the Supporting Information). Likewise, the conversion of **3** ( $M_r$ =384.65) yielded a product with an identical m/z [M+H]<sup>+</sup> (Figure S2). Both results strongly suggest the hydroxylation of VD<sub>3</sub> (**1**) and proVD<sub>3</sub> (**3**).

To unambiguously determine the regioselectivity of the reaction, the products were characterized by NMR spectroscopy. The <sup>1</sup>H and <sup>13</sup>C NMR spectra of authentic **1** and **3** standards were highly similar to their products **2** and **4**, respectively, with the exception of the chemical shifts for C26, C27 methyl groups (<sup>1</sup>H spectra), and C25 (<sup>13</sup>C spectra). For **1** and **3**, the C26 and C27 methyl groups are observed as doublets at  $\delta = 0.86$  ppm in the <sup>1</sup>H spectra. For **2** and **4**, the <sup>1</sup>H NMR signal for CH<sub>3</sub>-26,27 is observed as a singlet at  $\delta = 1.23$  ppm. A downfield shift is observed in the <sup>13</sup>C NMR spectrum for the C25 signal ( $\delta = 71.1$  ppm versus 22.8 ppm for **1** and **3**), thus indicating the hydroxylation of C25, as described for 25-hydroxycholest-4-en-3-one.<sup>[11]</sup>

The <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data are in perfect agreement with those published for 25OHVD<sub>3</sub>.<sup>[14]</sup> The complete NMR spectroscopic data are presented in the Supporting Information (<sup>1</sup>H and <sup>13</sup>C NMR spectra/shifts, 2D NMR spectra for **2**, and <sup>1</sup>H NMR spectrum of **4**; Figures S3–S5 and Table S1).

To identify the enzyme(s) involved in  $VD_3$  (1) hydroxylation, we enriched the activity from extracts of cells grown with cholesterol. After four chromatographic steps, four Communications



**Figure 3.** Enrichment of the VD<sub>3</sub> (1) hydroxylating enzyme. A) Relative specific conversion rates of VD<sub>3</sub> (1, grey columns) and cholest-4-en-3-one (black columns) obtained during the solubilization and purification steps. a) cell extract; b) solubilized membrane fraction; c–f) fractions obtained after chromatography on DEAE-Sepharose, ceramic hydroxyapatite, Reactive Red agarose, and Mono Q anion exchange chromatography, respectively. B) SDS gel of enriched enzyme after four chromatographic steps. Left lane: bands 1–3 were identified as  $\alpha\beta\gamma$ -subunits of C25DH; band 4 is a degradation product of band 1 (Table S2). Right lane: Molecular mass standard with masses in kDa as indicated.

protein bands were highly enriched with a specific VD<sub>3</sub> (1) hydroxylation activity of 80 nmol min<sup>-1</sup> mg<sup>-1</sup> (Figure 3 A). Mass spectrometric analysis of tryptic digests of the enriched protein bands identified the  $\alpha\beta\gamma$ -subunits of C25DH (JQ292991-3) plus a fourth band corresponding to a degradation product of the  $\alpha$ -subunit (JQ292991; Table S2). After each purification step, the relative specific hydroxylation rates of VD<sub>3</sub> (1) and cholest-4-en-3-one<sup>[8]</sup> remained almost constant in all activity-containing fractions (around 70% with 1), thus confirming that both reactions are catalyzed by the same enzyme (Figure 3 B). VD<sub>3</sub> (1) hydroxylation activity was highest in extracts of cells grown with cholesterol (100%), and significantly lower in cells grown with sitosterol (18%), ergosterol (15%), or stigmasterol (5%), which is in line with the induction of C25DH during growth with cholesterol.

The conversion of cholest-4-en-3-one and proVD<sub>3</sub> (3) by C25DH was observed in the presence of various detergents and HPCD. In contrast, conversion of VD<sub>3</sub> (1) was negligible when HPCD was replaced by a number of commonly used detergents (Figure S6). This finding suggests that HPCD plays a specific role in VD<sub>3</sub> conversion rather than serving as a general solubilizing agent. The equilibrium preVD<sub>3</sub> (5)  $\rightleftharpoons$  VD<sub>3</sub> (1) through thermal [1,7] sigmatropic rearrangement lies far to the right in aqueous detergent solutions (Scheme 2, upper reaction).<sup>[12]</sup> However, in the presence of HPCD, an inclusion complex is formed at a 2:1 ratio (HPCD/VD<sub>3</sub>), in which the thermodynamically unfavorable *cZc* conformer of preVD<sub>3</sub> (5) is stabilized.<sup>[12]</sup> This finding led us to the assumption that preVD<sub>3</sub> (5) rather than VD<sub>3</sub> (1) is the actual substrate of C25DH.

By replacing the commonly used ethyl acetate for steroid extraction by n-hexane, more than 80% of VD<sub>3</sub> (1, 1 mM) added to the HPCD-containing assay mixture was identified as preVD<sub>3</sub> (5) by UPLC analysis. In the course of the enzymatic reaction, preVD<sub>3</sub> (5) was time-dependently converted into 25OHVD<sub>3</sub> (2), with virtually no formation of the expected 25OHpreVD<sub>3</sub> (6) intermediate (Figure 4). In con-



**Scheme 2.** Proposal for HPCD-dependent hydroxylation of VD<sub>3</sub> by C25DH. In the presence of HPCD, the equilibrium between VD<sub>3</sub> (1) and preVD<sub>3</sub> (5), which are interconverted through a thermal [1,7] hydrogen shift, is shifted to the right. The *cZc* conformer of **5** is likely the substrate for C25DH. The hydroxylated **6** was not detected owing to rapid isomerization to **2**.



**Figure 4.** UPLC analysis of enzymatic VD<sub>3</sub> (1) hydroxylation in the presence of HPCD after steroid extraction with *n*-hexane. At t=0 h, before enzyme addition, around 80% of the added VD<sub>3</sub> was HPCD-dependently isomerized into preVD<sub>3</sub> (5).

trast, during extraction with ethyl acetate,  $preVD_3$  (5) was never identified during  $VD_3$  (1) hydroxylation (Figure 1 A). To substantiate the HPCD-dependent conversion of  $VD_3$  (1) into  $preVD_3$  (5) as an essential process for enzymatic sidechain hydroxylation, we replaced  $VD_3$  (1) by authentic  $preVD_3$  (5) and observed an identical product pattern as during  $VD_3$  (1) conversion (Figure S7). The rates of  $VD_3$  (1) and  $preVD_3$  (5) hydroxylation were nearly identical, thus suggesting that the HPCD-dependent conversion of  $VD_3$  (1) into  $preVD_3$  (5) is not rate limiting.

In summary, the results indicate that  $preVD_3$  (5) but not  $VD_3$  (1) is the substrate for C25DH. The failure to detect any trace of a 25-OH-preVD<sub>3</sub> intermediate indicates a rapid isomerization into 25OHVD<sub>3</sub> (Scheme 2).

The procedure presented in this work represents a new enzymatic route for the regioselective hydroxylation of  $VD_3$ 

(1),  $proVD_3$  (3), and  $preVD_3$  (5) at C25, and expands our knowledge of tertiary alcohol synthesis.<sup>[13]</sup> Since cell extracts of S. denitrificans can be used for these reactions, it circumvents tedious enzyme purification or genetic manipulation procedures and offers a facile method for a mechanistically demanding chemical reaction. The method strictly depends on HPCD for  $VD_3$  (1) solubilization and isomerization and represents a novel example of substrate-range expansion. In comparison to CYP-dependent hydroxylations it does not depend on electron-donor systems. The only cofactor used,  $K_3[Fe(CN)_6]$ , can be regenerated by electrodes as has been demonstrated for the related ethyl benzene dehydrogenase.<sup>[14]</sup> Moreover, the method does not depend on oxygen and nor is it oxygen sensitive. The synthetic method for 25OHVD<sub>3</sub> synthesis may be useful for the treatment of 25OHVD<sub>3</sub> deficiencies and to satisfy the increasing demand for monitoring of its levels in blood plasma.

## Acknowledgements

This work was funded by DFG (BO 1565/11-1) in frame of the Scientific Priority Programme SPP1319. We thank Dr. P. Bisel, Freiburg, for help with NMR measurements.

**Keywords:** biotechnology  $\cdot$  C–H activation  $\cdot$  enzyme catalysis  $\cdot$  steroids  $\cdot$  vitamins

How to cite: Angew. Chem. Int. Ed. 2016, 55, 1881–1884 Angew. Chem. 2016, 128, 1913–1916

 a) M. F. Holick, N. Engl. J. Med. 2007, 357, 266–281; b) S. V. Ramagopalan, A. Heger, A. J. Berlanga, N. J. Maugeri, M. R. Lincoln, A. Burrell, L. Handunnetthi, A. E. Handel, G. Disanto, S. M. Orton, C. T. Watson, J. M. Morahan, G. Giovannoni, C. P. Ponting, G. C. Ebers, J. C. Knight, *Genome Res.* 2010, 20, 1352– 1360.

- [2] a) M. Wacker, M. F. Holick, *Nutrients* 2013, 5, 111–148; b) A. Hossein-nezhad, M. F. Holick, *Mayo Clin. Proc.* 2013, 88, 720–755.
- [3] C. J. Farrell, S. Martin, B. McWhinney, I. Straub, P. Williams, M. Herrmann, *Clin. Chem.* 2012, 58, 531–542.
- [4] G. D. Zhu, W. H. Okamura, Chem. Rev. 1995, 95, 1877–1952.
- [5] D. Nicoletti, A. Mourino, M. Torneiro, J. Org. Chem. 2009, 74, 4782–4786.
- [6] a) K. Hayashi, H. Sugimoto, R. Shinkyo, M. Yamada, S. Ikeda, S. Ikushiro, M. Kamakura, Y. Shiro, T. Sakaki, *Biochemistry* 2008, 47, 11964–11972; b) K. Hayashi, K. Yasuda, H. Sugimoto, S. Ikushiro, M. Kamakura, A. Kittaka, R. L. Horst, T. C. Chen, M. Ohta, Y. Shiro, T. Sakaki, *FEBS J.* 2010, 277, 3999–4009; c) D. J. Kang, J. H. Im, J. H. Kang, K. H. Kim, *Bioprocess Biosyst. Eng.* 2015, 38, 1281–1290; d) D. J. Kang, J. H. Im, J. H. Kang, K. H. Kim, *Biotechnol. Lett.* 2015, 37, 1895–1904; e) T. Sakaki, H. Sugimoto, K. Hayashi, K. Yasuda, E. Munetsuna, M. Kamakura, S. Ikushiro, Y. Shiro, *Biochim. Biophys. Acta Proteins Proteomics* 2011, *1814*, 249–256; f) K. Yasuda, M. Endo, S. Ikushiro, M. Kamakura, M. Ohta, T. Sakaki, *Biochem. Biophys. Res. Commun.* 2013, 434, 311–315; g) Y. Yasutake, T. Nishioka, N. Imoto, T. Tamura, *ChemBioChem* 2013, *14*, 2284–2291.
- [7] E. D. Babot, J. C. Del Rio, M. Canellas, F. Sancho, F. Lucas, V. Guallar, L. Kalum, H. Lund, G. Grobe, K. Scheibner, R. Ullrich, M. Hofrichter, A. T. Martinez, A. Gutierrez, *Appl. Environ. Microbiol.* 2015, *81*, 4130–4142.
- [8] J. Dermer, G. Fuchs, J. Biol. Chem. 2012, 287, 36905-36916.
- [9] R. Hille, J. Hall, P. Basu, Chem. Rev. 2014, 114, 3963-4038.
- [10] S. Fuse, Y. Mifune, N. Tanabe, T. Takahashi, Org. Biomol. Chem. 2012, 10, 5205 – 5211.
- [11] Y. R. Chiang, W. Ismail, M. Müller, G. Fuchs, J. Biol. Chem. 2007, 282, 13240-13249.
- [12] X. Q. Tian, M. F. Holick, J. Biol. Chem. 1995, 270, 8706-8711.
- [13] M. Müller, ChemBioEng. Rev. 2014, 1, 14-26.
- [14] P. Kalimuthu, J. Heider, D. Knack, P. V. Bernhardt, J. Phys. Chem. B 2015, 119, 3456-3463.

Received: November 6, 2015 Published online: December 22, 2015